Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer

Summary

Up to 18 women with ovarian cancer will administer up to two injections of SPL-108 daily in combination with weekly doses of Paclitaxel. They will be monitored for safety and efficacy for up to 6 months, until disease progression or unacceptable toxicity.

Timeline

Start

2017-03-10

Primary completion

2020-01-31

Completion

2020-06-30

Publications

• Girda E, Hou J, Nelson D, Finlayson M, de Meritens AB, Chekmareiva M, Leiser A, Song M, Stephenson R, Chan N, Tergas AI, Vattakalam R, Wright JD, Yu H, Martincuks A, Kohut A, Palmer J, Rodriguez-Rodriguez L. Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer. Int J Gynecol Cancer. 2022 Aug 1;32(8):1032-1038. doi: 10.1136/ijgc-2021-003316.

Drugs

Indications